\-\ Texto\\:\\ \ \(0\)\
\-\ bp\\ 123\\/69\\,\\ bmi\\ 26\ \(0\)\
\-\ abdomen\\:\\ no\\ organomegaly\\,\\ masses\\,\\ tenderness\\.\\ \\ non\\-distended\\,\\ positive\\ bowel\\ sounds\\.\ \(0\)\
\-\ back\\ \\&\\ spine\\:\\ \\ no\\ costovertebral\\ angle\\ tenderness\\.\\ \\ no\\ point\\ tenderness\\.\ \(0\)\
\-\ extremities\\:\\ no\\ edema\ \(0\)\
\-\ neuro\\:\\ \\ a\\&o\\ x3\\,\\ no\\ focal\\ neurological\\ deficits\\.\\ \\ \ \(0\)\
\-\ the\\ rest\\ of\\ her\\ exam\\ was\\ non\\-contributory\\,\\ including\\ a\\ normal\\ ua\\.\ \(0\)\
\-\ there\\ is\\ no\\ specific\\ treatment\\ to\\ delay\\ or\\ prevent\\ the\\ progression\\ of\\ the\\ disease\\.\\ \\ symptomatic\\ treatment\\ of\\ pain\\ is\\ warranted\\ but\\ nonsteroidal\\ anti\\-inflammatory\\ drugs\\ are\\ discouraged\\ due\\ to\\ risk\\ of\\ exacerbation\\ of\\ renal\\ failure\\ \\ also\\,\\ tight\\ blood\\ pressure\\ control\\ is\\ needed\\ and\\ should\\ be\\ monitored\\ to\\ track\\ renal\\ failure\\ progression\\.\\ \\ many\\ deaths\\ from\\ adpkd\\ are\\ the\\ result\\ of\\ ascvd\\.\\ \\ in\\ addition\\,\\ lots\\ of\\ fluids\\ are\\ encouraged\\,\\ while\\ caffeine\\ should\\ be\\ avoided\\,\\ to\\ suppress\\ antidiuretic\\ hormone\\ secretion\\ and\\ prevent\\ stone\\ formation\\ \\(5\\)\\.\ \(0\)\
\-\ follow\\ up\\:\\ \ \(0\)\
\-\ \\â\\€\\¢genetic\\ counseling\\ with\\ possibility\\ of\\ testing\\ of\\ family\\ members\ \(0\)\
\-\ \\â\\€\\¢symptomatic\\ treatment\\ and\\ watching\\ renal\\ function\ \(0\)\
\-\ \\â\\€\\¢ultrasound\\ of\\ kidneys\\ for\\ baseline\\ and\\ anatomy\ \(0\)\
\-\ mri\\ showed\\ multiple\\ renal\\ cysts\\.\\ \\ the\\ largest\\ measures\\ 4\\.7\\ cm\\ in\\ maximal\\ dimension\\ and\\ is\\ in\\ the\\ upper\\ pole\\ of\\ the\\ right\\ kidney\\.\\ \\ additional\\ smaller\\ cysts\\ are\\ present\\ in\\ both\\ kidneys\\,\\ with\\ approximately\\ 4\\ moderate\\ sized\\ ones\\ in\\ the\\ right\\ kidney\\ and\\ 4\\ moderate\\ sized\\ ones\\ in\\ the\\ left\\ kidneys\\.\ \(0\)\
\-\ autosomal\\ dominant\\ polycystic\\ kidney\\ disease\\ \\(adpkd\\)\ \(0\)\
\-\ adpkd\\ \\(autosomal\\ dominant\\)\ \(0\)\
\-\ tuberous\\ sclerosis\\ \\(may\\ also\\ have\\ renal\\ angiomyolipoma\\)\ \(0\)\
\-\ von\\ hippel\\-lindau\\ \\(may\\ have\\ cns\\ hemangioblastoma\\)\ \(0\)\
\-\ other\\ cystic\\ disease\\ of\\ the\\ kidney\\:\ \(0\)\
\-\ acquired\\ renal\\ cystic\\ disease\\,\\ arpkd\\ \\(autosomal\\ recessive\\)\\,\\ medullary\\ cystic\\ disease\\,\\ simple\\ renal\\ cysts\\.\\ \\ arpkd\\ can\\ be\\ differentiated\\ from\\ adpkd\\ by\\ the\\ hepatic\\ fibrosis\\ that\\ is\\ always\\ present\\ in\\ patients\\ with\\ arpkd\\.\ \(0\)\
\-\ patient\\ had\\ chronic\\ lower\\ back\\/hip\\ pain\\ for\\ four\\ years\\ that\\ got\\ worse\\ 2\\ weeks\\ prior\\ to\\ admission\\.\\ \\ the\\ pain\\ is\\ reproducible\\ with\\ lifting\\,\\ walking\\,\\ standing\\ over\\ half\\ an\\ hour\\ and\\ sitting\\ too\\ long\\.\ \(0\)\
\-\ she\\ was\\ seen\\ by\\ orthopedics\\ who\\ think\\ the\\ back\\ pain\\ is\\ musculoskeletal\\,\\ however\\,\\ she\\ still\\ needs\\ interval\\ renal\\ function\\ tests\\ and\\ monitoring\\.\\ \\ the\\ fact\\ that\\ she\\ has\\ this\\ many\\ cysts\\ at\\ such\\ a\\ young\\ age\\ is\\ a\\ bad\\ prognostic\\ sign\\.\\ \\ also\\,\\ she\\ will\\ need\\ counseling\\ on\\ the\\ genetics\\ of\\ her\\ disease\\.\ \(0\)\
\-\ Keywords\\ by\\ value\\:\\ \ \(0\)\
\-\ adpkd\\:\\ 0\\.0596738661337684\ \(0\)\
\-\ arpkd\\:\\ 0\\.05558022989660803\ \(0\)\
\-\ renal\\:\\ 0\\.05122145734579689\ \(0\)\
\-\ autosomal\\:\\ 0\\.036989905833356165\ \(0\)\
\-\ cysts\\:\\ 0\\.033391105065649546\ \(0\)\
\-\ ones\\:\\ 0\\.033008946865986426\ \(0\)\
\-\ counseling\\:\\ 0\\.03013930025798861\ \(0\)\
\-\ kidney\\:\\ 0\\.030028762643890372\ \(0\)\
\-\ kidneys\\:\\ 0\\.029421819212320153\ \(0\)\
\-\ sized\\:\\ 0\\.025569271670087587\ \(0\)\
\-\ she\\:\\ 0\\.023928041311263564\ \(0\)\
\-\ 123\\/69\\:\\ 0\\.021983836468744383\ \(0\)\
\-\ ascvd\\:\\ 0\\.021983836468744383\ \(0\)\
\-\ lots\\:\\ 0\\.021983836468744383\ \(0\)\
\-\ antidiuretic\\:\\ 0\\.021983836468744383\ \(0\)\
\-\ \\â\\€\\¢genetic\\:\\ 0\\.021983836468744383\ \(0\)\
\-\ \\â\\€\\¢symptomatic\\:\\ 0\\.021983836468744383\ \(0\)\
\-\ \\â\\€\\¢ultrasound\\:\\ 0\\.021983836468744383\ \(0\)\
\-\ back\\/hip\\:\\ 0\\.021983836468744383\ \(0\)\
\-\ dominant\\:\\ 0\\.02175147694619945\ \(0\)\
\-\ progression\\:\\ 0\\.021202844052362405\ \(0\)\
\-\ prevent\\:\\ 0\\.021151159328993096\ \(0\)\
\-\ disease\\:\\ 0\\.02089881607804046\ \(0\)\
\-\ discouraged\\:\\ 0\\.020255289883806864\ \(0\)\
\-\ caffeine\\:\\ 0\\.020255289883806864\ \(0\)\
\-\ tenderness\\:\\ 0\\.019443234335772816\ \(0\)\
\-\ watching\\:\\ 0\\.018526743298869344\ \(0\)\
\-\ cystic\\:\\ 0\\.018438648682681483\ \(0\)\
\-\ function\\:\\ 0\\.01806763876846029\ \(0\)\
\-\ many\\:\\ 0\\.01751727439355323\ \(0\)\
\-\ deaths\\:\\ 0\\.01751560836593128\ \(0\)\
\-\ nonsteroidal\\:\\ 0\\.017131192705514175\ \(0\)\
\-\ \\:\\:\\ 0\\.01691184263327678\ \(0\)\
\-\ 4\\.7\\:\\ 0\\.016798196713931825\ \(0\)\
\-\ got\\:\\ 0\\.016798196713931825\ \(0\)\
\-\ moderate\\:\\ 0\\.016759088820991502\ \(0\)\
\-\ failure\\:\\ 0\\.016695552532824773\ \(0\)\
\-\ suppress\\:\\ 0\\.016504473432993213\ \(0\)\
\-\ bad\\:\\ 0\\.016504473432993213\ \(0\)\
\-\ costovertebral\\:\\ 0\\.016241729004918833\ \(0\)\
\-\ avoided\\:\\ 0\\.016241729004918833\ \(0\)\
\-\ reproducible\\:\\ 0\\.016004047758524008\ \(0\)\
\-\ secretion\\:\\ 0\\.015787061780993757\ \(0\)\
\-\ think\\:\\ 0\\.015787061780993757\ \(0\)\
\-\ encouraged\\:\\ 0\\.015587454031184441\ \(0\)\
\-\ x3\\:\\ 0\\.015402646120576657\ \(0\)\
\-\ genetics\\:\\ 0\\.015230594071980767\ \(0\)\
\-\ members\\:\\ 0\\.015069650128994305\ \(0\)\
\-\ \\&\\:\\ 0\\.014969515671528337\ \(0\)\
\-\ tight\\:\\ 0\\.014775926848055695\ \(0\)\
\-\ hippel\\-lindau\\:\\ 0\\.014513182419981313\ \(0\)\
\-\ bmi\\:\\ 0\\.014275501173586488\ \(0\)\
\-\ prognostic\\:\\ 0\\.014275501173586488\ \(0\)\
\-\ recessive\\:\\ 0\\.014164648897848749\ \(0\)\
\-\ back\\:\\ 0\\.01406018122367819\ \(0\)\
\-\ fluids\\:\\ 0\\.01405851519605624\ \(0\)\
\-\ track\\:\\ 0\\.013956714710968323\ \(0\)\
\-\ maximal\\:\\ 0\\.013858907446246922\ \(0\)\
\-\ should\\:\\ 0\\.013587075021889277\ \(0\)\
\-\ organomegaly\\:\\ 0\\.013586590009925245\ \(0\)\
\-\ lifting\\:\\ 0\\.013586590009925245\ \(0\)\
\-\ warranted\\:\\ 0\\.013502047487043247\ \(0\)\
\-\ anti\\-inflammatory\\:\\ 0\\.013502047487043247\ \(0\)\
\-\ needs\\:\\ 0\\.013502047487043247\ \(0\)\
\-\ von\\:\\ 0\\.013420277355315093\ \(0\)\
\-\ non\\-distended\\:\\ 0\\.013341103544056786\ \(0\)\
\-\ exacerbation\\:\\ 0\\.013264366240648423\ \(0\)\
\-\ sitting\\:\\ 0\\.013117631826626145\ \(0\)\
\-\ o\\:\\ 0\\.012979053644195196\ \(0\)\
\-\ treatment\\:\\ 0\\.01293977775262509\ \(0\)\
\-\ orthopedics\\:\\ 0\\.012912549287381827\ \(0\)\
\-\ no\\:\\ 0\\.012874476070381077\ \(0\)\
\-\ monitored\\:\\ 0\\.012847772513308858\ \(0\)\
\-\ angiomyolipoma\\:\\ 0\\.012847772513308858\ \(0\)\
\-\ \\,\\:\\ 0\\.012826661458425087\ \(0\)\
\-\ her\\:\\ 0\\.012815020740573245\ \(0\)\
\-\ baseline\\:\\ 0\\.012604285058037245\ \(0\)\
\-\ polycystic\\:\\ 0\\.012604285058037245\ \(0\)\
\-\ also\\:\\ 0\\.012603139104764224\ \(0\)\
\-\ dimension\\:\\ 0\\.012228168126030803\ \(0\)\
\-\ hormone\\:\\ 0\\.012082859128215403\ \(0\)\
\-\ largest\\:\\ 0\\.012082859128215403\ \(0\)\
\-\ too\\:\\ 0\\.011945552950701618\ \(0\)\
\-\ 4\\:\\ 0\\.011875171596902968\ \(0\)\
\-\ drugs\\:\\ 0\\.01177350090210573\ \(0\)\
\-\ hemangioblastoma\\:\\ 0\\.01177350090210573\ \(0\)\
\-\ monitoring\\:\\ 0\\.01177350090210573\ \(0\)\
\-\ tuberous\\:\\ 0\\.01173228069773862\ \(0\)\
\-\ hour\\:\\ 0\\.011651829669763006\ \(0\)\
\-\ are\\:\\ 0\\.011619689501542161\ \(0\)\
\-\ acquired\\:\\ 0\\.011424967379973163\ \(0\)\
\-\ differentiated\\:\\ 0\\.011389085241688626\ \(0\)\
\-\ standing\\:\\ 0\\.011353712087095218\ \(0\)\
\-\ ua\\:\\ 0\\.011318833678180656\ \(0\)\
\-\ half\\:\\ 0\\.011250507059257675\ \(0\)\
\-\ is\\:\\ 0\\.011217771139844901\ \(0\)\
\-\ fact\\:\\ 0\\.011217033193092737\ \(0\)\
\-\ musculoskeletal\\:\\ 0\\.011151403995293801\ \(0\)\
\-\ tests\\:\\ 0\\.011151403995293801\ \(0\)\
\-\ that\\:\\ 0\\.011042249839592195\ \(0\)\
\-\ anatomy\\:\\ 0\\.011025110397242043\ \(0\)\
\-\ neuro\\:\\ 0\\.010994511662599115\ \(0\)\
\-\ always\\:\\ 0\\.01096428383084763\ \(0\)\
\-\ walking\\:\\ 0\\.01093441801776355\ \(0\)\
\-\ cns\\:\\ 0\\.010904905654554068\ \(0\)\
\-\ \\(\\:\\ 0\\.010808404881454271\ \(0\)\
\-\ possibility\\:\\ 0\\.010762365969167664\ \(0\)\
\-\ \\)\\:\\ 0\\.010676374445585612\ \(0\)\
\-\ need\\:\\ 0\\.010627534993431316\ \(0\)\
\-\ stone\\:\\ 0\\.010601422026181202\ \(0\)\
\-\ delay\\:\\ 0\\.010575579664496548\ \(0\)\
\-\ simple\\:\\ 0\\.010499621541093284\ \(0\)\
\-\ interval\\:\\ 0\\.010450238430628995\ \(0\)\
\-\ pain\\:\\ 0\\.010410056533972416\ \(0\)\
\-\ smaller\\:\\ 0\\.01033089673193165\ \(0\)\
\-\ testing\\:\\ 0\\.010307698745242589\ \(0\)\
\-\ medullary\\:\\ 0\\.010239372126319611\ \(0\)\
\-\ still\\:\\ 0\\.010151088018960717\ \(0\)\
\-\ angle\\:\\ 0\\.0100037341128011\ \(0\)\
\-\ pole\\:\\ 0\\.009923283084825487\ \(0\)\
\-\ 26\\:\\ 0\\.00986460354016166\ \(0\)\
\-\ be\\:\\ 0\\.00985852910232366\ \(0\)\
\-\ rest\\:\\ 0\\.009826237159015826\ \(0\)\
\-\ deficits\\:\\ 0\\.009751231036229598\ \(0\)\
\-\ control\\:\\ 0\\.009714557351966017\ \(0\)\
\-\ present\\:\\ 0\\.009625978822601898\ \(0\)\
\-\ fibrosis\\:\\ 0\\.009488486608155218\ \(0\)\
\-\ worse\\:\\ 0\\.00943910349769093\ \(0\)\
\-\ admission\\:\\ 0\\.009390679343433819\ \(0\)\
\-\ may\\:\\ 0\\.009348271166574183\ \(0\)\
\-\ point\\:\\ 0\\.009312005134618542\ \(0\)\
\-\ needed\\:\\ 0\\.009281217514114055\ \(0\)\
\-\ young\\:\\ 0\\.009281217514114055\ \(0\)\
\-\ bp\\:\\ 0\\.009250805361760393\ \(0\)\
\-\ four\\:\\ 0\\.009250805361760393\ \(0\)\
\-\ have\\:\\ 0\\.009229117597830882\ \(0\)\
\-\ neurological\\:\\ 0\\.009220759629799858\ \(0\)\
\-\ measures\\:\\ 0\\.009118361907112143\ \(0\)\
\-\ addition\\:\\ 0\\.009033819384230144\ \(0\)\
\-\ hepatic\\:\\ 0\\.008898988408493796\ \(0\)\
\-\ specific\\:\\ 0\\.008808764826006258\ \(0\)\
\-\ formation\\:\\ 0\\.00879613813783532\ \(0\)\
\-\ family\\:\\ 0\\.008733946246695039\ \(0\)\
\-\ additional\\:\\ 0\\.008544754848254357\ \(0\)\
\-\ sounds\\:\\ 0\\.008499617587297705\ \(0\)\
\-\ symptomatic\\:\\ 0\\.008466292829661376\ \(0\)\
\-\ pressure\\:\\ 0\\.008368909999556955\ \(0\)\
\-\ extremities\\:\\ 0\\.0083583207454885\ \(0\)\
\-\ result\\:\\ 0\\.0081750228352817\ \(0\)\
\-\ non\\-contributory\\:\\ 0\\.007870414484306426\ \(0\)\
\-\ risk\\:\\ 0\\.0077187198188505895\ \(0\)\
\-\ including\\:\\ 0\\.007694310825418762\ \(0\)\
\-\ sclerosis\\:\\ 0\\.007654152701811334\ \(0\)\
\-\ sign\\:\\ 0\\.007382659605396686\ \(0\)\
\-\ in\\:\\ 0\\.007356061374019412\ \(0\)\
\-\ long\\:\\ 0\\.007347185812550433\ \(0\)\
\-\ masses\\:\\ 0\\.007203472314204706\ \(0\)\
\-\ by\\:\\ 0\\.007096612983764961\ \(0\)\
\-\ spine\\:\\ 0\\.007017714578566952\ \(0\)\
\-\ showed\\:\\ 0\\.00698704056838827\ \(0\)\
\-\ positive\\:\\ 0\\.006914926659062635\ \(0\)\
\-\ follow\\:\\ 0\\.006771071002360184\ \(0\)\
\-\ while\\:\\ 0\\.006704860947262627\ \(0\)\
\-\ bowel\\:\\ 0\\.0066831758924806965\ \(0\)\
\-\ will\\:\\ 0\\.006667034958551476\ \(0\)\
\-\ such\\:\\ 0\\.006661677780151751\ \(0\)\
\-\ approximately\\:\\ 0\\.006593061911609932\ \(0\)\
\-\ age\\:\\ 0\\.0064860606622052525\ \(0\)\
\-\ from\\:\\ 0\\.006316387596779114\ \(0\)\
\-\ abdomen\\:\\ 0\\.006312678959839641\ \(0\)\
\-\ years\\:\\ 0\\.0062574641820909785\ \(0\)\
\-\ 5\\:\\ 0\\.006234814021057764\ \(0\)\
\-\ focal\\:\\ 0\\.006086018962938658\ \(0\)\
\-\ weeks\\:\\ 0\\.006048074206736031\ \(0\)\
\-\ edema\\:\\ 0\\.006027240622023169\ \(0\)\
\-\ chronic\\:\\ 0\\.006002467912486284\ \(0\)\
\-\ however\\:\\ 0\\.005933586173558779\ \(0\)\
\-\ blood\\:\\ 0\\.005816486465110473\ \(0\)\
\-\ up\\:\\ 0\\.00573029214726739\ \(0\)\
\-\ cm\\:\\ 0\\.005715601291314179\ \(0\)\
\-\ due\\:\\ 0\\.00568647669065546\ \(0\)\
\-\ who\\:\\ 0\\.005556030945490529\ \(0\)\
\-\ patients\\:\\ 0\\.005515148626847944\ \(0\)\
\-\ prior\\:\\ 0\\.005471602923197914\ \(0\)\
\-\ both\\:\\ 0\\.005441895238618756\ \(0\)\
\-\ over\\:\\ 0\\.005425542618802899\ \(0\)\
\-\ to\\:\\ 0\\.0053250387586407264\ \(0\)\
\-\ the\\:\\ 0\\.0051714196273176735\ \(0\)\
\-\ upper\\:\\ 0\\.005142345399921991\ \(0\)\
\-\ was\\:\\ 0\\.004929064948696692\ \(0\)\
\-\ other\\:\\ 0\\.004911816829681916\ \(0\)\
\-\ mri\\:\\ 0\\.004895949762879351\ \(0\)\
\-\ can\\:\\ 0\\.004833472200670996\ \(0\)\
\-\ lower\\:\\ 0\\.004792673489685443\ \(0\)\
\-\ exam\\:\\ 0\\.004681381396382888\ \(0\)\
\-\ had\\:\\ 0\\.0045981292250391725\ \(0\)\
\-\ 2\\:\\ 0\\.0045887892681061\ \(0\)\
\-\ but\\:\\ 0\\.004544896012552463\ \(0\)\
\-\ right\\:\\ 0\\.004496916254914796\ \(0\)\
\-\ multiple\\:\\ 0\\.004488294273015633\ \(0\)\
\-\ seen\\:\\ 0\\.004211041434084016\ \(0\)\
\-\ has\\:\\ 0\\.00400174556232987\ \(0\)\
\-\ a\\:\\ 0\\.003956107748813977\ \(0\)\
\-\ of\\:\\ 0\\.0037769311979397747\ \(0\)\
\-\ for\\:\\ 0\\.0036364496191656614\ \(0\)\
\-\ and\\:\\ 0\\.0035912021093709415\ \(0\)\
\-\ normal\\:\\ 0\\.003340679437902995\ \(0\)\
\-\ there\\:\\ 0\\.0031713604899376276\ \(0\)\
\-\ an\\:\\ 0\\.002946795172779875\ \(0\)\
\-\ at\\:\\ 0\\.0028871899073108056\ \(0\)\
\-\ or\\:\\ 0\\.002497562964996777\ \(0\)\
\-\ this\\:\\ 0\\.0023968509060202817\ \(0\)\
\-\ left\\:\\ 0\\.002384302417139438\ \(0\)\
\-\ patient\\:\\ 0\\.0021361394785944835\ \(0\)\
\-\ on\\:\\ 0\\.0018052144946768779\ \(0\)\
\-\ \\.\\:\\ 0\\.0017705504287953255\ \(0\)\
\-\ with\\:\\ 0\\.0011671239510213439\ \(0\)\
